This data, taken together, explain why vertical suppression of EGFR/MAPK pathway has only a transient effect in KRAS-driven colorectal cancers and stimulate new research on the best treatment approach for this aggressive cancer type, encouraging further evaluation of novel combination strategies including PI3K inhibitors. The gene discussed is KRAS; the disease is colorectal cancer.